Hints and tips:
Related Special Reports
...Bristol Myers Squibb raised $13bn in a large bond deal on Wednesday that will help fund two acquisitions....
...Bristol Myers Squibb launched a potentially jumbo-sized bond deal on Wednesday to help fund two acquisitions....
...Bristol Myers Squibb has agreed to buy neuroscience biotech Karuna Therapeutics for $14bn, gaining access to a promising schizophrenia drug....
...Bristol Myers Squibb has pushed out by one year its sales target for a new crop of drugs, guiding that the pharmaceutical company’s goal of at least $10bn would now not be achieved until 2026....
...Still, that has not stopped investors from fretting about pipeline replacement at companies such as Bristol Myers Squibb (BMS), Sanofi and Roche....
...Earnings: Aon, Bristol Myers Squibb, Danske Bank, Deutsche Bank, Electrolux, Ferrari and YouGov release results. Economic data: Monthly industrial production figures are to be published in France....
...Pharmaceutical company Bristol Myers Squibb fell 3.5 per cent after the federal US drug regulator delayed its decision to expand the use of a cancer therapy and as rival Bayer stopped a late-stage study...
...Last autumn the property data company TwentyCi reported that proximity to a farm shop significantly increased property prices....
...Pharma: Pharmaceutical groups Bristol Myers Squibb, Regeneron and AbbVie will also report earnings before the market opens....
...The impact could be significant for companies such as Bristol Myers Squibb. Its blood thinner Eliquis is expected to account for more than a quarter of sales in 2026, according to Visible Alpha....
...Oxford-based Exscientia is working with Sanofi and Bristol Myers Squibb, among others, and Insitro has a deal with Bristol Myers, while Owkin is also collaborating with Sanofi....
...A better look for the UK is GSK in a head-to-head with Bristol-Myers: This time, the UK company has stronger prospective earnings growth, due to Bristol’s patent expirations, as well as stronger returns...
...A price to forward earnings multiple of over 50 values the stock more like a tech company than a pharma group. Bristol Myers Squibb trades on just seven times earnings while Pfizer is on 20 times....
...Bristol Myers Squibb said on Wednesday that chief executive Giovanni Caforio would step down as chief executive on November 1 and be replaced by chief commercialisation officer Christopher Boerner....
...High-grade pharma group Bristol Myers Squibb sold $13bn of debt on Wednesday....
...Mirati, which was purchased by Bristol Myers Squibb in a deal announced last year, did not immediately respond to a request for comment....
...Myers Squibb would buy the biotech company....
...Other earnings: Merck, Bristol Myers Squibb, UPS, Northrop Grumman, Honeywell, Altria, Hershey, Mastercard and Royal Caribbean report earnings before the opening bell....
...But he was still glad he founded his tech company there — and could take advantage of the institution’s broader benefits....
...Professor Richard Martin, lead author and Cancer Research UK scientist at the University of Bristol, said: “The key takeaway is that the small reduction in prostate cancer deaths by using the test to screen...
...In the pharmaceutical industry, big companies including AstraZeneca, AbbVie and Bristol Myers Squibb have announced about $25bn worth of biotech-related deals....
...Other drugmakers including Merck, Bristol Myers Squibb, and Johnson & Johnson, as well as the US pharmaceutical lobby group, have already filed lawsuits against the reforms....
...Among them is PsiQuantum, a quantum computing company spun out from research at the University of Bristol. In 2021, the company was valued at $3.15bn....
...Pharmaceutical groups Bristol Myers Squibb, Regeneron and AbbVie are also expected to release earnings....
International Edition